A Pilot Study to Evaluate the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor AZD2171 and Chemotherapy in Locally Advanced and Inflammatory Breast Cancer

Saved in:
Bibliographic Details
Published inClinical breast cancer Vol. 6; no. 5; pp. 460 - 463
Main Authors Denduluri, Neelima, Tan, Antoinette R., Walshe, Janice, Berman, Arlene, Yang, Sherry X., Chow, Catherine K., Swain, Sandra M.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.12.2005
Subjects
Angiogenesis
Breast Neoplasms - drug therapy
Breast Neoplasms - etiology
Clinical Trials, Phase II as Topic
Docetaxel
Enzyme Inhibitors - adverse effects
Enzyme Inhibitors - therapeutic use
Female
Humans
Inflammation - drug therapy
Neoadjuvant chemotherapy
Pilot Projects
Quinazolines - adverse effects
Quinazolines - therapeutic use
Randomized Controlled Trials as Topic
Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors
Neoadjuvant chemotherapy
Angiogenesis
Docetaxel
Online AccessGet full text

Cover

More Information
ISSN:1526-8209
1938-0666
DOI:10.3816/CBC.2005.n.052